148 related articles for article (PubMed ID: 31200147)
1. Outcomes and second neoplasms in hairy cell leukemia: A retrospective cohort.
da Silva WF; Neto AC; da Rosa LI; de Siqueira IA; Amarante GD; Velloso EDRP; Rego EM; Rocha V; Buccheri V
Leuk Res; 2019 Aug; 83():106165. PubMed ID: 31200147
[TBL] [Abstract][Full Text] [Related]
2. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.
Robak T; Błasińska-Morawiec M; Błoński J; Hellmann A; Hałaburda K; Konopka L; Kotlarek-Haus S; Potoczek S; Hansz J; Dmoszyńska A; Urasiński I; Zdziarska B; Dwilewicz-Trojaczek J; Hołowiecki J; Skotnicki AB
Eur J Haematol; 1999 Jan; 62(1):49-56. PubMed ID: 9918312
[TBL] [Abstract][Full Text] [Related]
3. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine.
Goodman GR; Burian C; Koziol JA; Saven A
J Clin Oncol; 2003 Mar; 21(5):891-6. PubMed ID: 12610190
[TBL] [Abstract][Full Text] [Related]
4. Real-world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL-CLLEAR study.
Panovská A; Žák P; Jurková T; Arpáš T; Brychtová Y; Vašíková A; Hrabčáková V; Prchlíková A; Filipová M; Doubek M
Hematol Oncol; 2024 May; 42(3):e3280. PubMed ID: 38741354
[TBL] [Abstract][Full Text] [Related]
5. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment.
Bastie JN; Cazals-Hatem D; Daniel MT; D'Agay MF; Rabian C; Glaisner S; Noel-Walter MP; Dabout D; Flandrin G; Dombret H; Poisson D; Degos L; Castaigne S
Leuk Lymphoma; 1999 Nov; 35(5-6):555-65. PubMed ID: 10609793
[TBL] [Abstract][Full Text] [Related]
6. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial.
Chihara D; Kantarjian H; O'Brien S; Jorgensen J; Pierce S; Faderl S; Ferrajoli A; Poku R; Jain P; Thompson P; Brandt M; Luthra R; Burger J; Keating M; Ravandi F
Br J Haematol; 2016 Sep; 174(5):760-6. PubMed ID: 27301277
[TBL] [Abstract][Full Text] [Related]
7. Treatment of hairy cell leukemia-variant with cladribine.
Tetreault SA; Robbins BA; Saven A
Leuk Lymphoma; 1999 Oct; 35(3-4):347-54. PubMed ID: 10706459
[TBL] [Abstract][Full Text] [Related]
8. Treatment Outcomes Of Patients With Hairy Cell Leukaemia; A 16-Year Experience At A Tertiary Care Center In Pakistan.
Yousaf M; Khan MA; Iftikhar R; Chaudary QU; Shahbaz N; Ahmad U; Javed H
J Ayub Med Coll Abbottabad; 2022; 34(4):797-801. PubMed ID: 36566402
[TBL] [Abstract][Full Text] [Related]
9. Second malignancies in patients with hairy cell leukemia in british columbia: a 20-year experience.
Au WY; Klasa RJ; Gallagher R; Le N; Gascoyne RD; Connors JM
Blood; 1998 Aug; 92(4):1160-4. PubMed ID: 9694703
[TBL] [Abstract][Full Text] [Related]
10. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years.
Else M; Ruchlemer R; Osuji N; Del Giudice I; Matutes E; Woodman A; Wotherspoon A; Swansbury J; Dearden C; Catovsky D
Cancer; 2005 Dec; 104(11):2442-8. PubMed ID: 16245328
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis.
Else M; Dearden CE; Matutes E; Garcia-Talavera J; Rohatiner AZ; Johnson SA; O'Connor NT; Haynes A; Osuji N; Forconi F; Lauria F; Catovsky D
Br J Haematol; 2009 Jun; 145(6):733-40. PubMed ID: 19344416
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia.
Cornet E; Tomowiak C; Tanguy-Schmidt A; Lepretre S; Dupuis J; Feugier P; Devidas A; Mariette C; Leblond V; Thiéblemont C; Validire-Charpy P; Sutton L; Gyan E; Eisenmann JC; Cony-Makhoul P; Ysebaert L; Troussard X;
Br J Haematol; 2014 Aug; 166(3):390-400. PubMed ID: 24749839
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population.
Madanat YF; Rybicki L; Radivoyevitch T; Jagadeesh D; Dean R; Pohlman B; Kalaycio M; Sekeres MA; Smith MR; Hill BT
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):857-862. PubMed ID: 28778620
[TBL] [Abstract][Full Text] [Related]
14. Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian Cooperative Group for HCL.
Federico M; Frassoldati A; Lamparelli T; Foà R; Brugiatelli M; Annino L; Baldini L; Capnist G; Chisesi T; di Celle PF
Ann Oncol; 1994 Oct; 5(8):725-31. PubMed ID: 7826905
[TBL] [Abstract][Full Text] [Related]
15. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence.
Else M; Dearden CE; Matutes E; Forconi F; Lauria F; Ahmad H; Kelly S; Liyanage A; Ratnayake V; Shankari J; Whalley I; Catovsky D
Leuk Lymphoma; 2011 Jun; 52 Suppl 2():75-8. PubMed ID: 21504288
[TBL] [Abstract][Full Text] [Related]
16. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience.
Chadha P; Rademaker AW; Mendiratta P; Kim B; Evanchuk DM; Hakimian D; Peterson LC; Tallman MS
Blood; 2005 Jul; 106(1):241-6. PubMed ID: 15761021
[TBL] [Abstract][Full Text] [Related]
17. Multicenter retrospective analysis regarding the clinical manifestations and treatment results in patients with hairy cell leukemia: twenty-four year Turkish experience in cladribine therapy.
Hacioglu S; Bilen Y; Eser A; Sivgin S; Gurkan E; Yildirim R; Aydogdu I; Dogu MH; Yilmaz M; Kayikci O; Tombak A; Kuku I; Celebi H; Akay MO; Esen R; Korkmaz S; Keskin A
Hematol Oncol; 2015 Dec; 33(4):192-8. PubMed ID: 25393847
[TBL] [Abstract][Full Text] [Related]
18. Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC).
López Rubio M; Da Silva C; Loscertales J; Seri C; Baltasar P; Colado E; Pérez Fernández I; Osma M; Gomis F; González M; Jarque I; Vargas M; Monzó E; Monteagudo D; Orts MI; Pardal E; Carbonell F; Perez Calvo C; Garcia-Marco JA
Leuk Lymphoma; 2014 May; 55(5):1007-12. PubMed ID: 23885799
[TBL] [Abstract][Full Text] [Related]
19. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia.
Else M; Osuji N; Forconi F; Dearden C; Del Giudice I; Matutes E; Wotherspoon A; Lauria F; Catovsky D
Cancer; 2007 Nov; 110(10):2240-7. PubMed ID: 17886250
[TBL] [Abstract][Full Text] [Related]
20. Combined treatment with splenectomy and cladribine in hairy cell leukemia in Taiwan: a clinicopathologic study of 5 cases.
Yu YB; Li CY; Chen CC; You JY; Chau WK; Hsu HC; Gau JP; Chen PM; Ho CH
J Chin Med Assoc; 2007 Dec; 70(12):551-5. PubMed ID: 18194897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]